# MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

> **NCT01239355** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 15 (actual)

## Conditions studied

- Adult Hepatocellular Carcinoma
- Advanced Adult Hepatocellular Carcinoma
- Localized Non-Resectable Adult Liver Carcinoma
- Recurrent Adult Liver Carcinoma

## Interventions

- **DRUG:** Akt Inhibitor MK2206
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01239355
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Early termination for discouraging results
- **Last updated:** 2015-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01239355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01239355, "MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01239355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*